Business Wire

CA-CHUGAI-PHARMACEUTICAL

4.12.2018 02:02:07 CET | Business Wire | Press release

Share
Results Presented from Primary Analysis of the Phase III HAVEN 2 Study with Chugai's HEMLIBRA® for Children with Hemophilia A with Inhibitors at the American Society of Hematology 2018

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that the primary analysis of the phase III HAVEN 2 study (NCT02795767), evaluating hemophilia A treatment HEMLIBRA® [generic name: emicizumab (genetical recombination)] in children with hemophilia A with factor VIII inhibitors, was reported in an Oral Presentation at the 60th American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 1 to 4 2018. These data, including longer follow-up (median of 11 additional months of data for once weekly dosing) and new data for less frequent dosing schedules (every two weeks or every four weeks), demonstrated clinically meaningful control of bleeding.

“Bleeding control is important especially for children with hemophilia A. I am happy that HEMLIBRA showed positive data from a longer period of treatment in children younger than 12 years of age with hemophilia A with inhibitors,” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “HEMLIBRA has been approved in more than 50 countries. I hope that the new data will broaden the potential contribution of HEMLIBRA in people with hemophilia A with inhibitors who have limited treatment options.”

HAVEN 2 Study

Study description

The HAVEN 2 study is a multicenter, open-label, clinical phase III study evaluating the efficacy, safety and pharmacokinetics of once weekly, every two weeks or every four weeks subcutaneous administration of HEMLIBRA prophylaxis in children younger than 12 years of age with hemophilia A with factor VIII inhibitors. The primary analysis on evaluation of efficacy included 85 children (once weekly dosing, Arm A, n=65; every two weeks dosing, Arm B, n=10; every four weeks dosing, Arm C, n=10) with hemophilia A with factor VIII inhibitors. The median follow-up period of Arm A, B and C was 58 (range 17.9–92.6), 21.3 (range 18.6–24.1), and 19.9 (range 8.9–24.1) weeks, respectively.

Study design n=85

  • HEMLIBRA prophylaxis was administered as follows.
 

Arm A
(n=65)

  Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 1.5 mg/kg once-weekly subcutaneous injection

Arm B
(n=10)

Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 3 mg/kg once every two weeks subcutaneous injection

Arm C
(n=10)

  Received HEMLIBRA prophylaxis at 3 mg/kg by once-weekly subcutaneous injection for 4 weeks, followed by 6 mg/kg once every four weeks subcutaneous injection
 
  • The prospective intra-patient comparison included 18 patients from the once weekly cohort (Arm A) previously treated with bypassing agents (BPAs) either as prophylaxis (n=15) or on-demand (n=3) as part of a non-interventional study.
 

Summary of results

Arm A
    Annualized bleeding rate [ABR] (95% CI)   Median ABR (Interquartile range; IQR)
Treated bleeds (primary endpoint) 0.3

(0.17; 0.50)

0.0

(0.00; 0.00)

All bleeds 3.2

(1.94; 5.22)

0.6

(0.00; 2.92)

Treated spontaneous bleeds 0.0

(0.01; 0.10)

0.0

(0.00; 0.00)

Treated joint bleeds 0.2

(0.08; 0.29)

0.0

(0.00; 0.00)

Treated target joint bleeds   Not estimable   0.0

(0.00; 0.00)

 
  Arm B Arm C
ABR, treated bleeds (95% CI) 0.2

(0.03; 1.72)

2.2

(0.69; 6.81)

Median ABR, treated bleeds (IQR) 0.0

(0.00; 0.00)

0.0

(0.00; 3.26)

% patients with zero treated bleeds

(95% CI)

90.0%

(55.5; 99.7)

60.0%

(26.2; 87.8)

% patients with 1-3 treated bleeds

(95% CI)

  10.0%

(0.3; 44.5)

  40.0%

(12.2; 73.8)

  • In patients receiving HEMLIBRA once weekly (Arm A), 76.9% (95% CI, 64.8; 86.5) experienced zero treated bleeds and 23.1% experienced 1–3 treated bleeds.
  • Once-weekly HEMLIBRA dosing showed a 99% (95% CI: 97.7 - 99.4) reduction in treated bleeds compared to prior treatment with bypassing agents (BPAs) as prophylaxis (n=15) or on-demand (n=3) in a prospective intra-patient comparison in Arm A.
  • The most common adverse reactions occurring in 10% or more of children treated with HEMLIBRA were common cold symptoms (nasopharyngitis; 37.5%), injection site reactions (29.5%), fever (pyrexia; 23.9%), upper respiratory tract infection (23.9%), cough (23.9%), diarrhoea (15.9%), vomiting (15.9%), headache (14.8%), contusion (12.5%), fall (12.5%) and influenza (10.2%).
  • No cases of thrombotic microangiopathy (TMA) or thrombotic events occurred.
  • Four patients tested positive for anti-drug antibodies (ADAs) to HEMLIBRA. Of these patients, two had ADAs with neutralizing potential based on reduced HEMLIBRA levels. As previously reported, the ADA in one of these patients resulted in reduced efficacy of HEMLIBRA and led to discontinuation of treatment. The other patient had no bleeds as of the clinical cut-off date of the study.

Also, the data from HOHOEMI study (JapicCTI-173710) were reported as a Poster Presentation at the ASH Annual Meeting. The HOHOEMI study is conducted in Japan by Chugai to investigate the efficacy, safety and pharmacokinetics of every two weeks or every four weeks subcutaneous administration of HEMLIBRA prophylaxis in children younger than 12 years of age with hemophilia A without inhibitors including pediatric patients previously untreated with FVIII.

About Chugai

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs, mainly focusing on the oncology area.
In Japan, Chugai’s research facilities in Gotemba and Kamakura are collaborating to develop new pharmaceuticals and laboratories in Ukima are conducting research for technology development for industrial production. Overseas, Chugai Pharmabody Research based in Singapore is engaged in research focusing on the generation of novel antibody drugs by utilizing Chugai’s proprietary innovative antibody engineering technologies. Chugai Pharma USA and Chugai Pharma Europe are engaged in clinical development activities in the United States and Europe.
The consolidated revenue in 2017 of Chugai totalled 534.2 billion yen and the operating income was 103.2 billion yen (IFRS Core basis).
Additional information is available on the internet at https://www.chugai-pharm.co.jp/english .

Trademarks used or mentioned in this release are protected by law.

Contact:

For Media Chugai Pharmaceutical Co., Ltd. Media Relations Group, Corporate Communications Dept., Tomoko Shimizu Tel: +81-3-3273-0881 E-mail: pr@chugai-pharm.co.jp

For US media Chugai Pharma USA Inc. Casey Astringer Tel: +1-908-516-1350 E-mail: pr@chugai-pharm.com

For European media Chugai Pharma France SAS Nathalie Leroy Tel: +33-1-56-37-05-21 E-mail: pr@chugai.eu

For Taiwanese media Chugai Pharma Taiwan Ltd. Susan Chou Tel: +886-2-2715-2000 E-mail: pr@chugai.com.tw

For Investors Chugai Pharmaceutical Co., Ltd. Investor Relations Group, Corporate Communications Dept., Toshiya Sasai Tel: +81-3-3273-0554 E-mail: ir@chugai-pharm.co.jp

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 17:00:00 CET | Press release

Canada becomes the 25th Allied nation to back the NATO Innovation Fund, gaining access to €1.1 billion in mission-aligned capital and a co-investor network spanning the Alliance Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the amb

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 15:30:00 CET | Press release

Independent evaluation of Persona's Android SDK confirms defenses against deepfakes and other injected media at the top level of the first standard Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 22:30:00 CET | Press release

Proposed facilitation of China Resources’ exit from Oatly requires a tender offer because of Swedish law requirements Verlinvest recommends that Oatly shareholders and holders of ADSs do not tender their shares or ADSs. Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 20:54:00 CET | Press release

With Picsart Platform, developers can build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. Key Takeaways One bundle, four ways to build: the API, the CLI, a playground to test models, and Picsart Media Studio, an MCP server that works with compatible AI assistants. One integration for image, video, audio and text generation from 250+ models across 30+ providers, with the freedom to switch models as a product evolves. Self-serve users pay per generation at competitive, published rates. Developers get access to Picsart's proprietary editing models, like Enhance and background removal, which are only available on Picsart Platform. Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 mil

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 18:45:00 CET | Press release

The Partnership brings together two brands committed to excellence, precision and exceptional experiences NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye